nach oben

Quality of Life Research

Erschienen in:

01.09.2012 | Brief Communication

Reliability and validity of PDQ-39: a quality-of-life measure for patients with PD in China

verfasst von: Jing-Lin Zhang, Piu Chan

Erschienen in: Quality of Life Research | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

The syndromes of Parkinson’s disease (PD) have impacts on health-related quality of life (HRQL). The 39-item Parkinson’s disease Questionnaire (PDQ-39) was the first specific and a consistent instrument for the evaluation of HRQL in PD patients.

Purpose

To test the reliability and validity of Chinese version PDQ-39.

Methods

Hundred and twenty-six PD without cognitive impairment were enrolled. The Chinese version of SF-36 was used to evaluate the congruent validity of PDQ-39 between related domains. Both PDQ-39 and SF-36 scales were fulfilled by the patients themselves.

Results

Five of eight subscales of PDQ-39 met the acceptable standards of reliability (Cronbach’s α coefficient >0.80), while the other three subscales (cognition, communication, and bodily discomfort) failed to reach the above standards as reported by the others. All the item-to-subscale correlations (range: 0.457–0.887) met the minimal acceptable item convergent validity criterion of 0.40 (P < 0.001). Correlation between PDQ-39 subscales and scales of the SF-36 had high negative correlations with a range of −0.759 to −0.124. Four of them had significant negative correlations (P < 0.0001).

Conclusions

The Chinese version of PDQ-39 is a reliable and valid instrument for Chinese PD patients. It is recommended as the most appropriate HRQL tool for PD.

Den Oudsten, B. L., Van Heck, G. L., & De Vries, J. (2007). Quality of life and related concepts in Parkinson’s disease: A systematic review. Movement Disorders, 22(11), 1528–1537.CrossRef

Shibley Rahman, H. J. G., Quinn, Niall. P., & Jahanshahi, Marjan. (2008). Quality of life in Parkinson’s disease: The relative importance of the symptoms. Movement Disorders, 23, 1428–1434.PubMedCrossRef

Janca, A. (1999). A report on the WHO working group on Parkinson’s disease. Neuroepidemiology, 18, 236–240.PubMedCrossRef

Schindler, J. S., Brown, R., Welburn, P., & Parkes, J. D. (1993). Measuring the quality of life of patients with Parkinson’s disease. In S. Walker & R. Rosser (Eds.). Quality of life assessment (pp. 289–300). Lancaster: Kluwer Academic.CrossRef

Martinez-Martin, P., & Frades Payo, B. (1998). Quality of life in Parkinson’s disease: Validation study of the PDQ-39 Spanish version. The Grupo Centro for study of movement disorders. Journal of Neurology, 245(1), S34–S38.PubMedCrossRef

Peto, V., Jenkinson, C., Fitzpatrick, R., & Greenhall, R. (1995). The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Quality of Life Research, 4(3), 241–248.PubMedCrossRef

Peto, V., Jenkinson, C., & Fitzpatrick, R. (1998). PDQ-39: A review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures. Journal of Neurology, 245(1), S10–S14.PubMedCrossRef

Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R., & Hyman, N. (1997). The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age and Ageing, 26(5), 353–357.PubMedCrossRef

Sullivan, M., Karlsson, J., & Ware, J. (1994). Halsoenkat SF-36. Svensk manual och tolkningsguide SF-36 health survey. Swedish mannual and interpretation guide.

10.

Tsang, K. L., Chi, I., Ho, S. L., Lou, V. W., Lee, T. M., & Chu, L. W. (2002). Translation and validation of the standard Chinese version of PDQ-39: a quality-of-life measure for patients with Parkinson’s disease. Movement Disorders, 17(5), 1036–1040.PubMedCrossRef

11.

Luo, N., Tan, L. C., Li, S. C., Soh, L. K., & Thumboo, J. (2005). Validity and reliability of the Chinese (Singapore) version of the Parkinson’s disease questionnaire (PDQ-39). Quality of Life Research, 14(1), 273–279.PubMedCrossRef

12.

Ma, H. I., Hwang, W. J., & Chen-Sea, M. J. (2005). Reliability and validity testing of a Chinese-translated version of the 39-item Parkinson’s disease questionnaire (PDQ-39). Quality of Life Research, 14(2), 565–569.PubMedCrossRef

13.

Katzman, R., Zhang, M. Y., Ouang Ya, Q., Wang, Z. Y., Liu, W. T., Yu, E., et al. (1988). A Chinese version of the mini-mental state examination; impact of illiteracy in a Shanghai dementia survey. Journal of Clinical Epidemiology, 41(10), 971–978.PubMedCrossRef

14.

Salmon, D. P., Riekkinen, P. J., Katzman, R., Zhang, M. Y., Jin, H., & Yu, E. (1989). Cross-cultural studies of dementia. A comparison of mini-mental state examination performance in Finland and China. Archives of Neurology, 46(7), 769–772.PubMedCrossRef

15.

Zhang, M. Y. (1993). The utilization of scales in the diagnosis of dementia. Chinese Journal of Practical Internal Medicine, 13(6), 337–339.

16.

Bushnell, D. M., & Martin, M. L. (1999). Quality of life and Parkinson’s disease: Translation and validation of the US Parkinson’s disease questionnaire (PDQ-39). Quality of Life Research, 8(4), 345–350.PubMedCrossRef

17.

Jenkinson, C. (1995). Self reported functioning and well being in patients with Parkinson’s disease. Comparison of the short form health survey (SF-36) and Parkinson disease questionnaire (PDQ-39). Age and Ageing, 24, 505–509.PubMedCrossRef

18.

de Boer, A. G., Wijker, W., Speelman, J. D., & de Haes, J. C. (1996). Quality of life in patients with Parkinson’s disease: Development of a questionnaire. Journal of Neurology, Neurosurgery and Psychiatry, 61(1), 70–74.CrossRef

19.

Ware, J. E., Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.PubMedCrossRef

20.

Calne, S. M., Mak, E., Hall, J., Fortin, M. J., King, P., McInnes, G., et al. (2003). Validating a quality-of-life scale in caregivers of patients with Parkinson’s disease: Parkinson’s Impact Scale (PIMS). Advances in Neurology, 91, 115–122.PubMed

21.

Hagell, P., Whalley, D., McKenna, S. P., & Lindvall, O. (2003). Health status measurement in Parkinson’s disease: validity of the PDQ-39 and Nottingham Health Profile. Movement Disorders, 18(7), 773–783.PubMedCrossRef

22.

Carod-Artal, F. J., Martinez-Martin, P., & Vargas, A. P. (2007). Independent validation of SCOPA-psychosocial and metric properties of the PDQ-39 Brazilian version. Movement Disorders, 22(1), 91–98.PubMedCrossRef

23.

Welsh, M., McDermott, M. P., Holloway, R. G., Plumb, S., Pfeiffer, R., & Hubble, J. (2003). Development and testing of the Parkinson’s disease quality of life scale. Movement Disorders, 18(6), 637–645.PubMedCrossRef

24.

Marinus, J., Ramaker, C., van Hilten, J. J., & Stiggelbout, A. M. (2002). Health related quality of life in Parkinson’s disease: A systematic review of disease specific instruments. Journal of Neurology, Neurosurgery and Psychiatry, 72(2), 241–248.CrossRef

25.

Auquier, P., Sapin, C., Ziegler, M., Tison, F., Destee, A., Dubois, B., et al. (2002). Validation of the French language version of the Parkinson’s disease questionnaire—PDQ-39. Review of Neurology (Paris), 158(1), 41–50.

26.

Martinez-Martin, P., Frades Payo, B., Fontan Tirado, C., Martinez Sarries, F. J., Guerrero, M. T., & del Ser Quijano, T. (1997). Assessing quality of life in Parkinson’s disease using the PDQ-39. A pilot study. Neurologia, 12(2), 56–60.PubMedCrossRef

27.

Souza, R. G., Borges, V., Silva, S. M., & Ferraz, H. B. (2007). Quality of life scale in Parkinson’s disease PDQ-39—(Brazilian Portuguese version) to assess patients with and without levodopa motor fluctuation. Arquivos de Neuropsiquiatr, 65(3B), 787–791.

28.

Tan, L. C., Luo, N., Nazri, M., Li, S. C., & Thumboo, J. (2004). Validity and reliability of the PDQ-39 and the PDQ-8 in English-speaking Parkinson’s disease patients in Singapore. Parkinsonism Relat Disord, 10(8), 493–499.PubMedCrossRef

29.

Martinez-Martin, P., Serrano-Duenas, M., & Vaca-Baquero, V. (2005). Psychometric characteristics of the Parkinson’s disease questionnaire (PDQ-39)–Ecuadorian version. Parkinsonism Relat Disord, 11(5), 297–304.PubMedCrossRef

30.

Katsarou, Z., Bostantjopoulou, S., Peto, V., Alevriadou, A., & Kiosseoglou, G. (2001). Quality of life in Parkinson’s disease: Greek translation and validation of the Parkinson’s disease questionnaire (PDQ-39). Quality of Life Research, 10(2), 159–163.PubMedCrossRef

31.

Jaeschke, R., Guyatt, G., & Spilker, B. (1990). How to develop and validate a new quality of life instrument. In B. Spilker (Ed.), Quality of life assessments in clinical trials. New York: Raven Press.

32.

Damiano, A. M., Snyder, C., Strausser, B., & Willian, M. K. (1999). A review of health-related quality-of-life concepts and measures for Parkinson’s disease. Quality of Life Research, 8(3), 235–243.PubMedCrossRef

33.

Kim, M. Y., Dahlberg, A., & Hagell, P. (2006). Respondent burden and patient-perceived validity of the PDQ-39. Acta Neurologica Scandinavica, 113(2), 132–137.PubMedCrossRef

Titel: Reliability and validity of PDQ-39: a quality-of-life measure for patients with PD in China
verfasst von: Jing-Lin Zhang
Piu Chan
Publikationsdatum: 01.09.2012
Verlag: Springer Netherlands
Erschienen in: Quality of Life Research / Ausgabe 7/2012
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-011-0026-1

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2012

Reliability of adverse symptom event reporting by clinicians

Measuring fatigue in persons with multiple sclerosis: creating a crosswalk between the Modified Fatigue Impact Scale and the PROMIS Fatigue Short Form

The anemia impact measure (AIM): development and content validation of a patient-reported outcome measure of anemia symptoms and symptom impacts in cancer patients receiving chemotherapy

Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample

The association between cumulative adversity and mental health: considering dose and primary focus of adversity

Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients